Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
Back

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

London-Camden Cardiff Coventry Glasgow

Medical Conditions

Colorectal Neoplasms
Microsatellite Instability

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2021 Jun 2026

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : 400 mg or 200 mg pembrolizumab administered via IV infusion.

Intervention Arm Group : Pembrolizumab;Pembrolizumab Plus MK-4830;

Intervention Type : BIOLOGICAL
Intervention Description : Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.

Intervention Arm Group : Pembrolizumab/Quavonlimab;

Intervention Type : BIOLOGICAL
Intervention Description : Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion

Intervention Arm Group : Pembrolizumab/Favezelimab;

Intervention Type : BIOLOGICAL
Intervention Description : Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion

Intervention Arm Group : Pembrolizumab/Vibostolimab;

Intervention Type : BIOLOGICAL
Intervention Description : 800 mg MK-4830 administered via IV infusion

Intervention Arm Group : Pembrolizumab Plus MK-4830;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • UCLH-Cancer Clinical Trials Unit ( Site 1402)
    London-Camden
    London, City Of
    NW1 2PG
  • Velindre Cancer Centre-Research and Development ( Site 1415)
    Cardiff
    CF14 2TL
  • University Hospital Coventry & Warwickshire ( Site 1406)
    Coventry
    CV2 2DX
  • Beatson West of Scotland Cancer Centre-Clinical Trials Unit ( Site 1401)
    Glasgow
    Glasgow City
    G12 0YN


The study is sponsored by Merck Sharp & Dohme LLC



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04895722
Last updated 11 December 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top